Vietnam Cardiac PoC Testing Devices Market 2026 - Top Regions, Latest Technology, Investment Opportunities, Future Trends and Outlook 2034

The Vietnam cardiac PoC testing devices market size was valued at USD 10.55 Million in 2025 and is projected to reach USD 16.69 Million by 2034, with a CAGR of 5.23% during 2026-2034. Growth is driven by government healthcare reforms and investments in medical infrastructure modernization. Rising cardiovascular health awareness and demand for rapid diagnostics accelerate point-of-care technology adoption. Integration of digital health and AI enhances diagnostic accuracy, reshaping healthcare delivery in Vietnam.

Study Assumption Years

Base Year: 2025

Historical Period: 2020-2025

Forecast Period: 2026-2034

Vietnam Cardiac PoC Testing Devices Market Key Takeaways

• The market size was USD 10.55 Million in 2025, with a CAGR of 5.23% forecasted to 2034.
• Cardiac markers test dominated product types with a 63% share in 2025.
• Hospitals led the end-user segment, holding 55% share in 2025.
• Growth accelerated by comprehensive government healthcare reforms and infrastructure modernization.
• Integration of AI and digital health solutions is enhancing clinical decision-making and instrument accuracy.
• Rising urbanization and disposable incomes are driving demand across private and public healthcare.

Sample Request Link: https://www.imarcgroup.com/vietnam-cardiac-poc-testing-devices-market/requestsample

Market Growth Factors

Rising Prevalence of Cardiovascular Diseases

Cardiovascular diseases remain the leading cause of mortality in Vietnam, fueling demand for rapid and accurate diagnostic solutions. Lifestyle changes linked to urbanization—such as sedentary behavior, dietary shifts, and increased stress—have increased cardiac conditions incidence across all ages. The growing burden from hypertension, diabetes, and obesity, as intermediate risk factors, amplifies cardiovascular disease prevalence. Healthcare providers prioritize early detection and continuous monitoring, driving stable investment in point-of-care testing infrastructure in hospitals and clinics nationwide.

Government Healthcare Investment and Infrastructure Development

The Vietnamese government is spearheading healthcare modernization with substantial funding for medical infrastructure. National strategies focus on advancing medical equipment capabilities and reducing reliance on overseas services. An example is the June 2024 Ministry of Health program aimed at early detection and management of non-communicable diseases and mental health disorders through 2025. Ambitious targets for hospital bed capacity and medical personnel ratios foster improvements in diagnostics accessibility. These initiatives facilitate procurement of advanced diagnostic tools while encouraging private sector expansion. Streamlined regulatory frameworks are easing market entry for innovative cardiac testing devices.

Technological Advancements in Diagnostic Testing

Advances in cardiac biomarker testing technology are expanding applications and improving diagnostic performance. High-sensitivity assays detect cardiac events earlier at lower biomarker concentrations, promoting timely interventions. Artificial intelligence and machine learning enhance result interpretation, reduce uncertainty, and support clinical decisions. Connected devices with cloud analytics enable real-time data sharing and trend monitoring, facilitating telemedicine and population health management. These innovations make point-of-care cardiac testing increasingly precise, accessible, and cost-effective for healthcare providers.

Market Segmentation

• Product Type:
• Cardiac Markers Test: Dominated the market with 63% share in 2025, noted for high specificity in myocardial injury detection and use in acute coronary syndrome diagnosis. Includes tests such as Cardiac Troponin (cTn), Myoglobin, Creatine Kinase MB Isoenzyme (CK-MB), Combinational Test Kits, and Brain Natriuretic Peptide (BNP) Test Analyzers.
• End User:
• Hospitals: Led the market with 55% share in 2025, driven by advanced infrastructure, high patient volume, and investments in diagnostic technologies. Hospitals benefit from quick biomarker results facilitating rapid clinical decisions, with major hospital networks integrating advanced cardiac diagnostics within digital health initiatives.
• Regions:
• Northern Vietnam: Including Hanoi, shows increasing demand due to higher cardiovascular disease prevalence, expanding healthcare infrastructure, and government-driven early detection and preventive care initiatives.
• Central Vietnam: Growth led by hospital network expansions in cities like Da Nang and Hue, increased cardiovascular risk awareness, and governmental healthcare and infrastructure investments.
• Southern Vietnam: Covers Ho Chi Minh City and Mekong Delta, characterized by urbanization-driven demand, lifestyle-related cardiac risks, and strong adoption of rapid diagnostic solutions across hospitals and clinics.

Regional Insights

Northern Vietnam, including Hanoi and surrounding provinces, is the dominant region for cardiac PoC testing devices with rising demand driven by increasing cardiovascular disease prevalence and growing healthcare awareness. Urban hospitals and diagnostic centers are expanding infrastructure, aided by government early detection programs. Rising disposable incomes and patient preference for rapid diagnostics bolster PoC device adoption across clinics and hospitals.

Recent Developments & News

In September 2025, South Korea's TR Group, supported by FPT Corporation, donated an AI-enabled Spirokit device for pulmonary function testing to Lam Dong General Hospital and Hue University of Medicine and Pharmacy, alongside a complimentary COPD screening program aiding over 700 residents. This marks the initial joint activity between FPT, TR, and Vietnamese hospitals under a cooperation agreement, highlighting progressive AI integration in cardiac diagnostics.

Key Players

• Multinational diagnostic corporations (names not specifically listed in source).

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302